Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Care Homes 1 Limited Annual Report and Financial Statements

Published

on

Reading Time: 13 minutes

EDINBURGH, Scotland–(BUSINESS WIRE)–Regulatory News:

Company Registered No: 05771789

CARE HOMES 1 LIMITED

ANNUAL REPORT AND FINANCIAL STATEMENTS

For the year ended 31 December 2018

       
CONTENTS Page
 
OFFICERS AND PROFESSIONAL ADVISERS 1
 
DIRECTORS’ REPORT 2
 
INDEPENDENT AUDITOR’S REPORT 6
 
PROFIT AND LOSS ACCOUNT 12
 
STATEMENT OF COMPREHENSIVE INCOME 13
 
BALANCE SHEET 14
 
STATEMENT OF CHANGES IN EQUITY 15
 
NOTES TO THE FINANCIAL STATEMENTS 16
 
 

OFFICERS AND PROFESSIONAL ADVISERS

DIRECTORS:

      S P Nixon
K D Pereira
L E Roberts
 
 

COMPANY SECRETARY:

NatWest Markets Secretarial Services Limited
 
 

REGISTERED OFFICE:

250 Bishopsgate
London
England
EC2M 4AA
 
 
 

INDEPENDENT AUDITOR:

Ernst & Young LLP
Statutory Auditor
25 Churchill Place
Canary Wharf
London
E14 5EY
 
 

Registered in England and Wales

DIRECTORS’ REPORT

The directors of Care Homes 1 Limited (“the Company”) present their
annual report together with the audited financial statements for the
year ended 31 December 2018.

ACTIVITIES AND BUSINESS REVIEW

The Directors’ report has been prepared in accordance with the
provisions available to companies entitled to the small companies
exemption and therefore does not include a Strategic report.

Activity

The principal activity of the Company continues to be that of an
investment business.

The directors do not anticipate any material change in either the type
or level of activities of the Company.

The Company is a part of The Royal Bank of Scotland Group plc (“the
Group”) which provides the Company with direction and access to all
central resources it needs and determines policies in all key areas such
as finance, risk, human resources or environment. For this reason, the
directors believe that performance indicators specific to the Company
are not necessary or appropriate for an understanding of the
development, performance or position of the business. The annual reports
of The Royal Bank of Scotland Group plc review these matters on a group
basis. Copies can be obtained from Corporate Governance and Regulatory
Affairs, The Royal Bank of Scotland Group plc, Gogarburn, Edinburgh,
EH12 1HQ, the Registrar of Companies or at www.rbs.com.

Review of the year

Business review

The directors are satisfied with the Company’s performance in the year.
The Company does not currently expect to make any further significant
investments in the foreseeable future.

Financial performance

The Company’s financial performance is presented on page 13 to 16.

The operating loss for the year was £108,579 (2017: profit of £15,415).
The retained loss for the year was £108,579 (2017: profit of £15,415).

The directors do not recommend the payment of a dividend (2017: nil).

At the end of the year the Balance Sheet showed total assets of
£118,428,761 (2017: £126,376,502) including income-generating assets
comprising loans and receivables of £108,880,182 (2017: £111,846,675)
together representing an decrease of 6.29%. Total shareholders’ funds
were £7,346,566 (2017: £11,220,242).

Principal risks and uncertainties

The Company seeks to minimise its exposure to financial risks other than
credit risk.

Management focuses on both the overall balance sheet structure and the
control, within prudent limits, of risk arising from mismatches,
including currency, maturity, interest rate and liquidity. It is
undertaken within limits and other policy parameters set by the Group
Asset and Liability Management Committee (Group ALCO).

The principal risks associated with the company are as follows:

Operational risk

Operational risks are inherent in the Company’s business. Operational
risk losses occur as the result of fraud, human error, missing or
inadequately designed processes, failed systems, damage to physical
assets, improper behaviour or from external events. The key mitigating
processes and controls include risk and control assessment, scenario
analysis, loss data collection, new product approval process, key risk
indicators, notifiable events process and the self certification
process. The implementation of these processes and controls is
facilitated and overseen by operational risk teams, with internal audit
providing independent evaluation of the control framework.

Interest rate risk

Structural interest rate risk arises where assets and liabilities have
different repricing maturities.

The Company manages interest rate risk by monitoring the consistency in
the interest rate profile of its assets and liabilities, and limiting
any re-pricing mismatches.

Liquidity risk

Liquidity risk arises where assets and liabilities have different
contractual maturities. Management focuses on risk arising from the
mismatch of maturities across the balance sheet and from undrawn
commitments and other contingent obligations.

Credit risk

The objective of credit risk management is to enable the Company to
achieve appropriate risk versus reward performance whilst maintaining
credit risk exposure in line with approved appetite for the risk that
customers will be unable to meet their obligations to the Company.

The key principles of the group’s Credit Risk Management Framework are
set out below:

  • Approval of all credit exposure is granted prior to any advance or
    extension of credit;
  • An appropriate credit risk assessment of the customer and credit
    facilities is undertaken prior to approval of credit exposure. This
    includes a review of, amongst other things, the purpose of credit and
    sources of repayment, compliance with affordability tests, repayment
    history, capacity to repay, sensitivity to economic and market
    developments and risk-adjusted return;
  • Credit risk authority is delegated by the Board and specifically
    granted in writing to all individuals involved in the granting of
    credit approval. In exercising credit authority, the individuals act
    independently of any related business revenue origination; and
  • All credit exposures, once approved, are effectively monitored and
    managed and reviewed periodically against approved limits. Lower
    quality exposures are subject to a greater frequency of analysis and
    assessment.

Market risk

Market risk is the potential for loss as a result of adverse changes in
risk factors including interest rates and equity prices together with
related parameters such as market volatilities.

The Company is exposed to market risk as a result of the assets and
liabilities contained within the Company’s balance sheet. There has been
no change to the nature of the Company’s exposure to market risks or the
manner in which it manages and measures the risk.

The main component of market risk that the Company faces is interest
rate risk. The Company manages interest rate risk by monitoring the
interest rate profile of its assets and liabilities.

Going concern

The directors, having a reasonable expectation that the Company has
adequate resources to continue in operational existence for the
foreseeable future, have prepared the financial statements on a going
concern basis.

DIRECTORS AND SECRETARY

The present directors and secretary, who have served throughout the year
except where noted below, are listed on page 1.

From 1 January 2018 to date the following changes have taken place:

Secretary       Appointed       Resigned
RBS Secretarial Services Limited 23 August 2018
NatWest Markets Secretarial Services Limited 23 August 2018
 

DIRECTORS’ RESPONSIBILITIES STATEMENT

The directors are responsible for preparing the annual report and the
financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare a Directors’ report and
financial statements for each financial year. Under that law, the
directors have elected to prepare the financial statements in accordance
with Financial Reporting Standard (FRS) 101 Reduced Disclosure
Framework, and must not approve the financial statements unless they are
satisfied that they give a true and fair view of the state of affairs at
the end of the year and the profit or loss of the Company for that
period. In preparing these financial statements, the directors are
required to:

  • select suitable accounting policies and then apply them consistently;
  • make judgements and estimates that are reasonable and prudent;
  • state whether FRS 101 has been followed; and
  • make an assessment of the Company’s ability to continue as a going
    concern.

The directors are responsible for keeping adequate accounting records
that are sufficient to show and explain the Company’s transactions and
disclose with reasonable accuracy at any time the financial position of
the Company and to enable them to ensure that Directors’ report and
financial statements comply with the requirements of the Companies Act
2006. They are also responsible for safeguarding the assets of the
Company and hence for taking reasonable steps for the prevention and
detection of fraud and other irregularities.

To the best of our knowledge, the financial statements for the year
ending 31 December 2018 for the issuer (“Care Homes 1 Limited”) have
been prepared in accordance Financial Reporting Standards 101 Reduced
Disclosure Framework, and give a true and fair view of the assets,
liabilities, financial position and profit of Care Homes 1 Limited. We
can also confirm that the Directors’ report includes a fair review of
the development and performance of the business and the position of Care
Homes 1 Limited, together with a description of the principal risks and
uncertainties that it faces.

This statement addresses section 4.a. (i) of the circular issued by the
Commission de Surveillance du Secteur Financier, Luxembourg.

DISCLOSURE OF INFORMATION TO AUDITOR

Each of the directors at the date of approval of this report confirms
that:

  • so far as they are aware, there is no relevant audit information of
    which the Company’s auditor is unaware; and
  • directors have taken all the steps that they ought to have taken to
    make themselves aware of any relevant audit information, and to
    establish that the Company’s auditor is aware of that information.

This confirmation is given and shall be interpreted in accordance with
the provisions of section 418 of the Companies Act 2006.

AUDITOR

Ernst & Young LLP has expressed its willingness to continue in office as
auditor.

Approved by the Board of Directors and signed on its behalf:

The accounts have been prepared in accordance with the provisions
applicable to companies subject to the small companies’ regime.

Director

Date:

INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF CARE HOMES 1 LIMITED

Opinion

We have audited the financial statements of Care Homes 1 Limited for the
year ended 31 December 2018 which comprise Profit and loss account,
Statement of Comprehensive Income, Balance Sheet, Statement of Changes
in Equity and the related notes 1 to 13 including a summary of
significant accounting policies. The financial reporting framework that
has been applied in their preparation is applicable law and United
Kingdom Accounting Standards including FRS 101 “Reduced Disclosure
Framework (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

  • give a true and fair view of the company’s affairs as at 31 December
    2018 and of its loss for the year then ended;
  • have been properly prepared in accordance with United Kingdom
    Generally Accepted Accounting Practice; and
  • have been prepared in accordance with the requirements of the
    Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on
Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under
those standards are further described in the Auditor’s responsibilities
for the audit of the financial statements section of our report below.
We are independent of the company in accordance with the ethical
requirements that are relevant to our audit of the financial statements
in the UK, including the FRC’s Ethical Standard as applied to listed
public interest entities, and we have fulfilled our other ethical
responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and
appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in
relation to which the ISAs (UK) require us to report to you where:

  • the directors’ use of the going concern basis of accounting in the
    preparation of the financial statements is not appropriate; or
  • the directors have not disclosed in the financial statements any
    identified material uncertainties that may cast significant doubt
    about the company’s ability to continue to adopt the going concern
    basis of accounting for a period of at least twelve months from the
    date when the financial statements are authorised for issue.

Overview of our audit approach

Key audit matters      
  • Inappropriate valuation of derivatives, associated income and
    the related cash movement in cash flow hedging reserves
  • Inappropriate amortisation of the debt securities
Materiality      
  • Overall planning materiality of £1,184,288 which represents 1%
    of Total Assets
     

Key audit matters.

Key audit matters are those matters that, in our professional judgment,
were of most significance in our audit of the financial statements of
the current period and include the most significant assessed risks of
material misstatement (whether or not due to fraud) that we identified.
These matters included those which had the greatest effect on: the
overall audit strategy, the allocation of resources in the audit; and
directing the efforts of the engagement team. These matters were
addressed in the context of our audit of the financial statements as a
whole, and in our opinion thereon, and we do not provide a separate
opinion on these matters.

Risk

  Our response to the risk   Key observations communicated to those charged with governance

Inappropriate valuation of derivatives, associated income and
the related movement in cash flow hedging reserves

 

The Company has securitisation debt which was assumed by the
entity from a historical transaction when RBS acquired the Nursing
Homes Property group of companies. The entity then entered into a
floating rate deposit and a swap agreement with RBS that would
enable the entity to meet the ongoing interest obligations and
ultimate repayment obligations under the bonds. A derivative asset
is recognised in the financial statements from this transaction.

 

The valuation of the derivative instruments involves significant
judgment which also poses risk of inappropriate revenue
recognition and movements in the cashflow hedge reserves.

 

The judgement in estimating fair value of the instrument can
involve complex valuation models and significant fair value
adjustments both of which may be reliant on data inputs where
there is limited market observability.

As part of the RBS group audit, we performed trade life-cycle
product walkthroughs to confirm our understanding of RBS’s process
and controls around revenue recognition relating to financial
instruments with higher risk characteristics.

 

We tested the design and operating effectiveness of the Group’s
controls over financial instrument valuations, including
independent price verification, model approval/review, collateral
management, and income statement analysis and reporting.

 

We obtained the underlying trade contract and verified the
existence and ownership of recorded derivatives as well as the
underlying terms of the instruments and we engaged our derivative
valuation experts to test the fair value of derivatives and the
appropriate recording in the financial statements in accordance
with the entity’s accounting policies and FRS 101. With the
support from our internal financial instrument valuation
specialists, we performed an independent valuation of the interest
rate derivative.

 

We evaluated the hedging relationship and verified that all
conditions for the cash flow hedging relationships are in
accordance with the entity’s accounting policies and the Financial
Reporting Standards.

 

We have also corroborated the revenue on the derivative in the
year by independently recalculating the interest and further
ensured that reserves carried forward from prior periods and
movements in the year are appropriate.

We concluded to those charged with governance that based on the
procedures performed, we are satisfied that the derivative assets,
associated interest income and the related cash flow hedge
reserves as at 31 December 2018 are fairly stated.

 

However, we note that there was a sub-LIBOR element of
ineffectiveness identified that had been incorrectly recognised on
designation of the cash flow hedge reserve.

 

This resulted in a reclassification from the cash flow hedge
reserve to retained earnings in the current year to correct the
ineffectiveness in the reserve on designation of the hedge. This
correction was not material and therefore did not require a
restatement of 2017 balances.

         

Inappropriate amortisation of the debt securities

 

In terms of IFRS 9, financial liabilities are initially measured
at fair value and subsequently measured at amortised cost. The
amortised cost of a financial instrument is defined as the amount
at which it was measured at initial recognition minus principal
repayments, plus or minus the cumulative amortisation using the
effective interest method. The effective interest method is a
method of calculating the amortised cost of a financial instrument
(or group of instruments) and of allocating the interest expense
over the relevant period.

 

Due to the complexity of the calculation, there is a risk that the
amortisation using the effective interest rate method is
incorrectly calculated, resulting in the closing balance of the
debt security being incorrect as well as the interest recognised
in the income statement.

During the RBS group audit, we tested the design and operating
effectiveness of the Group’s key controls over the debt securities.

 

We performed the procedures below as part of our substantive
procedures;

 

We obtained the novation agreement when the entity assumed the
liability as well as the original issuance documents (prospectus)
to understand the terms of the agreements.

 

We reviewed the amortisation of the instruments using the
effective interest rate, including calculation and allocation of
the finance costs to the appropriate periods to determine the
amortised cost at year end.

 

We reviewed the contracts for compliance with terms and tested
whether the entity is meeting the agreed contractual obligations,
including coupon payments. We noted that the entity is meeting its
obligations in terms of the contract.

 

 

We concluded to those charged with governance that based on the
procedures performed, we are satisfied that the debt securities
are fairly stated and appropriate disclosures have been included
in the financial statements.

         

An overview of the scope of our audit.

Tailoring the scope

Our assessment of audit risk, our evaluation of materiality and our
allocation of performance materiality determine our audit scope for the
company. This enables us to form an opinion on the financial statements.
We consider size, risk profile, the organisation of the company and
effectiveness of controls, including controls and changes in the
business environment when assessing the level of work to be performed.

All audit work was performed directly by the audit engagement team,
except for the valuation of the derivative asset at year end, which was
valued by our valuation specialists as noted in key matters above.

Our application of materiality

We apply the concept of materiality in planning and performing the
audit, in evaluating the effect of identified misstatements on the audit
and in forming our audit opinion.

Materiality

The magnitude of an omission or misstatement that, individually or in
the aggregate, could reasonably be expected to influence the economic
decisions of the users of the financial statements. Materiality provides
a basis for determining the nature and extent of our audit procedures.

We determined materiality for the company to be £1,184,288 (2017:
£112,000), which is 1% of Total Assets (2017: 1% of Equity). The reason
for selecting this measure as the basis for our audit materiality is
that NWM Plc fully owns and fund the entity and that the entity’s assets
are designed to fund the obligations arising on the bond issuance, which
has been fully acquired by NWM Plc. We therefore consider that the
assets are the primary focus to the users of the financial statements.

During the course of our audit, we reassessed initial materiality moving
from an Equity-based measure to Total Assets. This was mainly driven by
assessing the primary focus of the users of the financial statements,
being NWM Plc directors, who are focused on the assets of the entity, as
opposed to a relatively small share capital base.

Performance materiality

The application of materiality at the individual account or balance
level.
It is set at an amount to reduce to an appropriately low
level the probability that the aggregate of uncorrected and undetected
misstatements exceeds materiality.

Based on our risk assessments, together with our assessment of the
company’s overall control environment, our judgement was that
performance materiality was 50% (2017: 50%) of our planning materiality,
namely £592,144 (2017: £56,000). We had set performance materiality at
this percentage due to audit differences identified in the prior year
audit requiring adjustments to both balances in 2017 and prior year
accounts.

Reporting threshold

An amount below which identified misstatements are considered as
being clearly trivial.

We agreed with those charged with governance that we would report to
them all uncorrected audit differences exceeding £59,214 (2017: £5,600),
which is set at 5% of planning materiality, as well as differences below
that threshold that, in our view, warranted reporting on qualitative
grounds.

We evaluate any uncorrected misstatements against both the quantitative
measures of materiality discussed above and considering other relevant
qualitative considerations in forming our opinion.

Other information

The other information comprises the information included in the
directors’ report set out on pages 2 to 5. The directors are responsible
for the other information.

Our opinion on the financial statements does not cover the other
information and, except to the extent otherwise explicitly stated in
this report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our
responsibility is to read the other information and, in doing so,
consider whether the other information is materially inconsistent with
the financial statements or our knowledge obtained in the audit or
otherwise appears to be materially misstated. If we identify such
material inconsistencies or apparent material misstatements, we are
required to determine whether there is a material misstatement in the
financial statements or a material misstatement of the other
information. If, based on the work we have performed, we conclude that
there is a material misstatement of the other information, we are
required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken during the audit:

  • the information given in the directors’ report for the financial year
    for which the financial statements are prepared is consistent with the
    financial statements; and
  • the directors’ report has been prepared in accordance with applicable
    legal requirements.

Contacts

Care Homes 1 Limited

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care

Published

on

Continue Reading

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania